NCT06803030

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 189 (estimated)
• Sponsor: Bir Hospital · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Detailed description

Ureteral stent related symptoms can be a major issue in patient undergoing stent placement after any procedure such as- complains of pain, urinary symptoms, sex related and work related and other symptoms. These symptoms can be alleviated with use of drugs such as Tamsulosin, Solifenacin and Mirabegron. Patient recruited in each arm of the study will have their stent related symptoms scoring done using a validated outcome assessment tool to measure the ureteral stent-related symptoms, Ureteral Stent Symptom Questionnaire (USSQ) on day 1, day 7 and day 14 after the stent placement.

Conditions

• Ureteral Stent-Related Symptom

Interventions

Type	Name	Description
DRUG	Tamsulosin Hydrochloride 0.4 mg	placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
DRUG	Solifenacin Succinate 5 mg	placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
DRUG	Mirabegron 25 mg	placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily

Timeline

• Start date: 2025-08-30
• Primary completion: 2025-12-01
• Completion: 2026-12-31
• First posted: 2025-01-31
• Last updated: 2025-09-08

Locations

1 site across 1 country: Nepal